SCHEMBL4486948

SCHEMBL4486948

O=C(CN1CCCC1)Nc1cccc(C(=O)NCCN2CCC(OC(=O)N(c3ccccc3-c3ccccc3)N(C(=O)O)c3ccccc3-c3ccccc3)CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.44
HPGD P15428 1/20 0.43
ATR Q13535 2/20 0.42
SMYD2 Q9NRG4 1/20 0.41
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
DRD4 P21917 1/20 0.40
HTR7 P34969 2/20 0.40
TRPV1 Q8NER1 2/20 0.40
HTR1A P08908 1/20 0.40
CARM1 Q86X55 1/20 0.40
PRMT6 Q96LA8 1/20 0.40
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
APP P05067 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480537 0.95 EPHX2 (0.43) EPHX2ATRMEN1KMT2ADRD4
SCHEMBL4470548 0.94 ATR (0.44) EPHX2ATRSMYD2POLBMEN1
SCHEMBL4477850 0.93 ALDH1A1 (0.48) EPHX2ATRPOLBMEN1KMT2A
SCHEMBL4486950 0.93 EPHX2 (0.46) EPHX2HPGDATRSMYD2POLB
SCHEMBL4470442 0.90 CARM1 (0.46) EPHX2HTR7HTR1ACARM1PRMT6
SCHEMBL4480375 0.90 EPHX2 (0.44) EPHX2ATRHTR7HTR1ACARM1
SCHEMBL4494143 0.90 EPHX2 (0.44) EPHX2ATRHTR7HTR1ACARM1
SCHEMBL4480181 0.89 CARM1 (0.47) EPHX2HTR7HTR1ACARM1PRMT6
SCHEMBL4482918 0.89 EPHX2 (0.43) EPHX2HTR7HTR1ACARM1PRMT6
SCHEMBL4472540 0.89 EPHX2 (0.43) EPHX2ATRHTR7HTR1ACARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed